글로벌 대사 장애 치료제 시장 – 2029년까지의 산업 동향 및 예측

대사 장애 치료제 시장 분석 및 규모

대사 장애 치료제 시장은 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다. 고혈압, 심근병, 당뇨병 및 고콜레스테롤혈증의 증가는 대사 증후군 시장을 활성화합니다. 건강에 해로운 생활 방식의 적응, 일상 생활에서의 스트레스 증가 및 영양실조, 심장병이 있는 가족력과 같은 요인도 시장 성장을 증가시키고 있습니다. 많은 주요 시장 참여자가 약물 발견 및 개발에 많은 기여를 하고 있습니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 대사 장애 치료제 시장의 성장률을 분석합니다. 대사 장애 치료제 시장의 예상 CAGR은 언급된 예측 기간 동안 약 7.50%인 경향이 있습니다. 시장은 2021년에 620억 달러로 평가되었으며 2029년까지 1,105.8억 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

대사 장애 치료제 시장 범위 및 세분화

Market Definition

Metabolic syndrome is the condition of grouped diseases that occur together and increases the risk of   heart disease, stroke and type 2 diabetes. These conditions involve high blood sugar, abnormal cholesterol level, increased blood pressure, excess body fat around the waist, increased blood pressure. Having one of the diseases doesn’t mean patient suffering from metabolic syndrome but, having two to three diseases at the same time increases the risk of metabolic syndrome. Symptom involves increased thirst & urination, blurred vision and fatigue. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Metabolic Disorders Therapeutics Market Dynamics

Drivers

• Rising Awareness For Disease Treatment

Increasing awareness among patients and several healthcare professionals for the treatment of different types of metabolic syndromes and more and more usage of combination therapy are the major factors that are expected to boost the demand for global metabolic syndrome market during the forecast period of 2022-2029.

• Increased Clinical Studies and Government Initiatives

The global metabolic syndrome market is projected to be driven by the rising R&D investments in drug discovery and development and the increasing prevalence of diabetes. For instance, as per the reports of International Diabetes Federation, for the treatment of diabetes as a metabolic syndrome, about 415 million people are currently affected by diabetes worldwide and it is hoped to increase to 642 million diabetic people by the year 2040.

Opportunities

• Increasing Demand for Retail Pharmacies

Increase in the number of metabolic syndromes therapeutics being delivered through retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

• Rising Demand of Drug Therapy

The drug therapy is driving the market because of its extensive usage as a result if ease of administration and high-reliability rate. This therapy is anticipated to maintain its growth even due to its advanced ways of administering medicines without disturbing daily patient lives. Furthermore, the launch of smart drug delivery devices and smart dosage control methods are projected to boost the segment further.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global metabolic disorders therapeutics market over a forecast period.

• High Cost

The huge expenditure of the treatment methods hamper the market growth.

This global metabolic disorders therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global metabolic disorders therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Metabolic Disorders Therapeutics Market

The Covid-19 pandemic let a negative impact on the global metabolic disorders therapeutics market because the utmost priority was given to Covid-19 patients for treatment. Numerous medical colleges and hospitals were reorganised and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. Discovery and development of drugs for the types of metabolic syndromes also slowed down during the pandemic, but it wasn’t in a pause and now in the post pandemic era, it is growing again.

Global Metabolic Disorders Therapeutics Market Scope

The global metabolic disorders therapeutics market is segmented on the basis of therapy type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy Type

• Enzyme Replacement Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy
• Others

Application

• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Hypercholesterolemia
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Metabolic Disorders Therapeutics Market Regional Analysis/Insights

The global metabolic disorders therapeutics market is analysed and market size insights and trends are provided by therapy type, application, distribution channel and end-user as referenced above.

The major countries covered in the global metabolic disorders therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to increased geriatric population, and presence of key manufacture of the product.

Asia-Pacific dominates the market due to increased prevalence of coronary heart diseases and related disorders, increased awareness programmes on the healthy lifestyle and number of generic drugs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Metabolic Disorders Therapeutics Market Share Analysis

The global metabolic disorders therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global metabolic disorders therapeutics market.

Key players operating in the global metabolic disorders therapeutics market include:

• Atkins Global (U.S.)
• Herbalife International of America Inc., (U.S.)
• Nutrisystem Inc., (U.S.)
• Abbott (U.S.)
• Kellogg Co. (U.S.)
• mega Laboratories, Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Medtronic (Ireland)
• Apollo Endosurgery Inc., (U.S.)
• GSK plc (U.K)
• Olympus Corporation (India)
• WW International Inc., (U.S.)
• jenny Craig (U.S.)
• Gold’s Gym  (U.S.)
• DSM (Netherlands)
• Brunswick  (U.S.)
• Amer Sports (Finland)
• Johnson Health Tech (U.S.)
• Technogym SpA (Italy)
• Shaklee Corporation (U.S.)
• Nature's Sunshine Products, Inc., (U.S.)
• Novo Nordisk A/S (Denmark)

SKU-54486